Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
J Dermatolog Treat. 2012 Aug;23(4):284-9. doi: 10.3109/09546634.2011.571657. Epub 2011 Jul 14.
Hidradenitis suppurativa (HS) is a chronic relapsing skin disease. Recent studies have shown promising results of anti-tumor necrosis factor-alpha treatment.
To compare the efficacy and safety of infliximab and adalimumab in the treatment of HS.
A retrospective study was performed to compare 2 cohorts of 10 adult patients suffering from severe, recalcitrant HS. In 2005, 10 patients were treated with infliximab intravenous (i.v.) (3 infusions of 5 mg/kg at weeks 0, 2, and 6). In 2009, 10 other patients were treated in the same hospital with adalimumab subcutaneous (s.c.) 40 mg every other week. Both cohorts were followed up for 1 year using identical evaluation methods [Sartorius score, quality of life index, reduction of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), patient and doctor global assessment, and duration of efficacy].
Nineteen patients completed the study. In both groups, the severity of the HS diminished. Infliximab performed better in all aspects. The average Sartorius score was reduced to 54% of baseline for the infliximab group and 66% of baseline for the adalimumab group.
Adalimumab s.c. 40 mg every other week is less effective than infliximab i.v. 5 mg/kg at weeks 0, 2, and 6.
化脓性汗腺炎（HS）是一种慢性复发性皮肤病。最近的研究表明，抗肿瘤坏死因子-α治疗有可喜的结果。
比较英夫利昔单抗和阿达木单抗治疗 HS 的疗效和安全性。
对 10 例成人严重难治性 HS 患者进行回顾性研究，比较两组患者。2005 年，10 例患者接受英夫利昔单抗静脉输注（i.v.）（5mg/kg，在第 0、2 和 6 周时输注 3 次）治疗。2009 年，在同一家医院，10 例患者接受阿达木单抗皮下（s.c.）40mg，每两周一次。两组患者均采用相同的评估方法（Sartorius 评分、生活质量指数、红细胞沉降率（ESR）和 C 反应蛋白（CRP）降低、患者和医生整体评估、疗效持续时间）进行为期 1 年的随访。
19 例患者完成了研究。两组患者的 HS 严重程度均有所减轻。英夫利昔单抗在各方面表现更佳。英夫利昔单抗组的平均 Sartorius 评分降至基线的 54%，阿达木单抗组降至基线的 66%。
阿达木单抗 s.c. 40mg，每两周一次，不如英夫利昔单抗 i.v. 5mg/kg，在第 0、2 和 6 周时效果好。
